Arunalight

Photobiomodulation for Early Dry AMD Gets Enthusiastic Reception

STOCKHOLM — A form of low-level light to stimulate cellular energy production achieved durable improvement in visual acuity in early-intermediate geographic atrophy (GA), a multicenter, sham-control study showed. Patients randomized to photobiomodulation (PBM) had a five- to six-letter improvement in best corrected visual acuity (BCVA) at 12 and 24 months. Most patients in the control […]

Photobiomodulation Using Light-Emitting Diode (LED) for Treatment of Retinal Diseases

Abstract: Photobiomodulation (PBM) is a type of phototherapy that employs light-emitting diodes (LEDs) or low-power lasers to selectively administer specific wavelengths of visible light, ranging from 500 to 1000 nm, including near-infrared (NIR) wavelengths. LEDs are advantageous compared to lasers due to their ability to treat large areas at a lower cost, lack of tissue damage […]

Photobiomodulation For Dry AMD: Ready For Its Day in The Sun?

In exudative age-related macular degeneration (wet AMD), significant strides — such as the development of anti-vascular endothelial growth factor (anti-VEGF) therapies — have pushed the treatment possibilities forward and rewritten the likely course of the disease for many patients. However, for most patients, AMD is nonexudative (dry), and treatments for those patients remain largely limited.1,2 Recent developments in […]

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review

Abstract Purpose Photobiomodulation therapy (PBT) has emerged as a possible treatment for age-related macular degeneration (AMD) and diabetic retinopathy (DR). This review seeks to summarize the application of PBT in AMD and DR. Methods The National Clinical Trial (NCT) database and PubMed were queried using a literature search strategy and reviewed by the authors. Results […]

Photobiomodulation as a Treatment in Dry AMD

The development of innovative treatments for debilitating diseases such as age-related macular degeneration (AMD) is crucial to advance patient care and to reduce burdens on patients, caregivers, and physicians. The dry, or nonexudative, form of AMD affects approximately 85% to 90% of individuals with AMD, and, until now, there have been no approved treatments for […]

Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration

Abstract Purpose: To evaluate the efficacy of photobiomodulation (PBM) treatment for patients with dry age-related macular degeneration (AMD). Methods: Assessments on 42 eyes with dry AMD (age related eye disease study (AREDS) 2-4) were conducted. Multiwavelength light emitting diode (LED) light comprising of yellow (590 nm), red (670 nm) and near-infrared (790 nm) bandwidths was applied to […]

A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION

Abstract Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3-4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, […]

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review

Abstract Purpose Photobiomodulation therapy (PBT) has emerged as a possible treatment for age-related macular degeneration (AMD) and diabetic retinopathy (DR). This review seeks to summarize the application of PBT in AMD and DR. Methods The National Clinical Trial (NCT) database and PubMed were queried using a literature search strategy and reviewed by the authors. Results […]

Shedding light on the importance of autophagy in AMD

Autophagy is a protective process that prevents oxidative damage in the eye. Recognition of this provides researchers with a new pathway to deal with age-related macular degeneration (AMD) and other retinal pathologies, according to Roberto Pinelli, MD, CEO and founder of the Switzerland Eye Research Institute, Lugano, Switzerland. He described the latest ideas about the […]

Select your currency
CAD Canadian dollar